199 related articles for article (PubMed ID: 28434854)
1. Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?
Kostine M; Stavris C; Chiche L
Eur J Cancer; 2017 Aug; 81():240-241. PubMed ID: 28434854
[No Abstract] [Full Text] [Related]
2. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
Quresh Q; Quinet R
J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
[No Abstract] [Full Text] [Related]
3. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.
Dehghani L; Mikail N; Kramkimel N; Soyer P; Lebtahi R; Mallone R; Larger E
Eur J Cancer; 2018 Nov; 104():243-246. PubMed ID: 30454710
[No Abstract] [Full Text] [Related]
5. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
6. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
9. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
Deltombe C; Garandeau C; Renaudin K; Hourmant M
Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
[No Abstract] [Full Text] [Related]
10. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
11. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
12. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
Akturk HK; Alkanani A; Zhao Z; Yu L; Michels AW
J Clin Endocrinol Metab; 2018 Oct; 103(10):3589-3592. PubMed ID: 30124874
[TBL] [Abstract][Full Text] [Related]
13. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
14. Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.
Quach HT; Dewan AK; Davis EJ; Ancell KK; Fan R; Ye F; Johnson DB
JAMA Oncol; 2019 Jun; 5(6):906-908. PubMed ID: 30998826
[TBL] [Abstract][Full Text] [Related]
15. Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.
Ogawa K; Kamimura K; Terai S
Hepatology; 2019 Feb; 69(2):914-916. PubMed ID: 30033637
[No Abstract] [Full Text] [Related]
16. Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.
Dimitriou F; Mangana J; Micaletto S; Braun RP; Dummer R
Melanoma Res; 2019 Feb; 29(1):107-108. PubMed ID: 30557221
[No Abstract] [Full Text] [Related]
17. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
Eur J Cancer; 2017 Aug; 81():203-205. PubMed ID: 28641200
[No Abstract] [Full Text] [Related]
18. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Fiset PO; Shapera S; Butler MO; Tsao MS
Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
[No Abstract] [Full Text] [Related]
19. Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature.
Gathings R; Lewallen R; Yosipovitch G
Acta Derm Venereol; 2015 Feb; 95(2):197-200. PubMed ID: 24820241
[TBL] [Abstract][Full Text] [Related]
20. What Have We Got to Lose?
McNeil CM
J Clin Oncol; 2016 Dec; 34(36):4443-4444. PubMed ID: 27998220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
